Mebeverine‐Loaded Electrospun Nanofibers: Physicochemical Characterization and Dissolution Studies

Both fast dissolving and sustained release drug delivery systems (DDSs) comprising mebeverine hydrochloride (MB‐HCl) embedded in either povidone (PVP) K60 or Eudragit® L 100‐55 nanofibers have been prepared by electrospinning. The fibers are found to have cylindrical morphologies with smooth surface...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2014-01, Vol.103 (1), p.283-292
Hauptverfasser: Illangakoon, Upulitha Eranka, Nazir, Tahir, Williams, Gareth R., Chatterton, Nicholas P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Both fast dissolving and sustained release drug delivery systems (DDSs) comprising mebeverine hydrochloride (MB‐HCl) embedded in either povidone (PVP) K60 or Eudragit® L 100‐55 nanofibers have been prepared by electrospinning. The fibers are found to have cylindrical morphologies with smooth surfaces, except at high drug loadings that appear to induce surface roughness (PVP) or fragmentation (Eudragit). There is a general increase in fiber diameter with drug loading. Differential scanning calorimetry and X‐ray diffraction demonstrate that the drug exists in an amorphous state in the fibers. Infrared spectroscopy data indicate that the drug has good compatibility with the polymer, whereas nuclear magnetic resonance spectroscopy and high‐performance liquid chromatography analyses confirmed that the MB‐HCl was not degraded during the spinning process. In vitro dissolution tests of the PVP fiber mats show them to dissolve within 10 s, an improved dissolution profile over the pure drug. The Eudragit fibers show pH‐dependent drug release profiles, with only very limited release at pH 2.0 but sustained release over approximately 8h at pH 6.8. The Eudragit nanofibers have the potential to be developed as oral DDSs for localized drug release in the intestinal tract, whereas the PVP materials may find the application as buccal delivery systems or suppositories. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:283–292, 2014
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.23759